- Home
- ACAD vs SBSW Comparison
ACAD vs SBSW Comparison
Compare ACAD & SBSW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- SBSW
- Stock Information
- Founded
- ACAD 1993
- SBSW 2013
- Country
- ACAD United States
- SBSW South Africa
- Employees
- ACAD N/A
- SBSW N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- SBSW Precious Metals
- Sector
- ACAD Health Care
- SBSW Basic Materials
- Exchange
- ACAD Nasdaq
- SBSW Nasdaq
- Market Cap
- ACAD 2.8B
- SBSW 2.3B
- IPO Year
- ACAD 2004
- SBSW N/A
- Fundamental
- Price
- ACAD $14.73
- SBSW $4.97
- Analyst Decision
- ACAD Buy
- SBSW Hold
- Analyst Count
- ACAD 16
- SBSW 4
- Target Price
- ACAD $23.93
- SBSW $5.05
- AVG Volume (30 Days)
- ACAD 1.8M
- SBSW 13.5M
- Earning Date
- ACAD 05-07-2025
- SBSW 04-29-2025
- Dividend Yield
- ACAD N/A
- SBSW N/A
- EPS Growth
- ACAD N/A
- SBSW N/A
- EPS
- ACAD 1.36
- SBSW N/A
- Revenue
- ACAD $957,797,000.00
- SBSW $5,938,469,800.00
- Revenue This Year
- ACAD $13.07
- SBSW $5.07
- Revenue Next Year
- ACAD $9.88
- SBSW $3.67
- P/E Ratio
- ACAD $10.83
- SBSW N/A
- Revenue Growth
- ACAD 31.85
- SBSW N/A
- 52 Week Low
- ACAD $13.40
- SBSW $3.05
- 52 Week High
- ACAD $20.68
- SBSW $5.91
- Technical
- Relative Strength Index (RSI)
- ACAD 38.07
- SBSW 66.65
- Support Level
- ACAD $14.34
- SBSW $3.18
- Resistance Level
- ACAD $15.18
- SBSW $3.76
- Average True Range (ATR)
- ACAD 0.80
- SBSW 0.29
- MACD
- ACAD -0.02
- SBSW 0.09
- Stochastic Oscillator
- ACAD 38.22
- SBSW 95.72
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About SBSW D/B/A Sibanye-Stillwater Limited ADS
Sibanye Stillwater Ltd is a South African mining and metals processing group with a diverse portfolio of operations, projects, and investments across five continents. The Group is also one of the foremost recyclers of PGM autocatalysts and has interests in mine tailings retreatment operations. It is a producer of platinum, palladium, and rhodium and is a top-tier gold producer. It also produces and refines iridium and ruthenium, nickel, chrome, copper, and cobalt. Its products are Gold, Nickel, Zinc, Chrome, PGMs, and other.